Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries

Launched by SHOCKWAVE MEDICAL, INC. · Apr 14, 2025

Keywords

ClinConnect Summary

The Disrupt PAD Japan study is looking at a new treatment called SWM-831 for people with a condition known as Peripheral Arterial Disease (PAD), which occurs when arteries in the legs become narrowed or blocked. This study is specifically focused on patients who have moderate to severe calcification (hardening) in the arteries of the thigh and knee area, known as the femoropopliteal arteries. The goal is to see if SWM-831 can help improve blood flow before they undergo other procedures, like balloon treatment or placing a stent.

To participate in this study, you need to be at least 18 years old and have certain types of blockages in your leg arteries. Some important requirements include having a specific level of artery narrowing and enough healthy blood flow to the foot. If you decide to take part, you will need to agree to all the study assessments and sign a consent form. As a participant, you can expect to receive careful monitoring and treatment, and your involvement will help researchers learn more about how to better manage PAD in patients with calcified arteries.

Gender

ALL

Eligibility criteria

• General Inclusion Criteria:
• Subjects are required to meet all of the following inclusion criteria in order to be enrolled in the clinical study:
• • 1. Subject is able and willing to comply with all assessments in the study.
• • 2. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the approved consent form.
• • 3. Age of subject is ≥ 18. Note: If a subject is under 20 years, voluntary agreement shall be obtained from both the subject and the subject's representative or legal guardian using the written consent form.
• • 4. Rutherford Clinical Category 2, 3, 4, or 5 of the target limb.
• • 5. Estimated life expectancy \> 1 year.
• Angiographic Inclusion Criteria:
• • Subjects are required to meet all of the following inclusion criteria in order to be enrolled in the clinical study. For lesion characteristics, each target lesion must meet eligibility.
• • 1. One target lesion that is located in a native, de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery). \<Not applicable to iliac or BTK cohort\>
• • 2. Target lesion reference vessel diameter (RVD) is between 4.0 mm and 8.0 mm by investigator visual estimate. \<Not applicable to iliac or BTK cohort\>
• • 3. Target lesion with ≥ 70% stenosis by investigator visual estimate.
• • 4. Target lesion length is ≤ 200 mm by investigator visual estimate. Target lesion can be all or part of the 200 mm treated zone.
• • 5. Subject has at least one patent tibial vessel on the target limb with runoff to the foot, defined as no stenosis ≥ 50%.
• • 6. Calcification is determined to be grade 2 - 4 (unilateral calcification ≥ 5 cm, bilateral wall calcification \< 5 cm, and bilateral calcification ≥ 5 cm, respectively), as defined by PACSS (Peripheral Artery Calcification Scoring System). \<Not applicable to iliac and BTK cohort\>
• • Angiographic Inclusion Criteria specific to Iliac Arteries
• • 1. Target lesion located in the native, de novo common or external iliac artery.
• • 2. Target lesion reference vessel diameter (RVD) is between 5.0 mm and 10.0 mm by investigator visual estimate.
• • 3. Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.
• • Note: Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis ≥ 50% and no serious angiographic complication.
• • Angiographic Inclusion Criteria specific to BTK Arteries
• • 1. Target lesion from the native, de novo distal segment of the popliteal artery to the ankle joint.
• • 2. Target lesion reference vessel diameter (RVD) is between 2.0 mm and 4.0 mm by investigator visual estimate.
• • 3. Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.
• • Note: Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis ≥ 50% and no serious angiographic complication.
• • General Exclusion Criteria
• Subjects who meet any of the following exclusion criteria may not be enrolled in the study:
• • 1. Rutherford Clinical Category 0, 1 and 6.
• • 2. Subject has known or suspected active infection evidenced by WBC \> 14.0 (14000/mm3) within 14 days prior to index procedure.
• • 3. Previous or planned target limb major amputation (above the ankle).
• • 4. History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure.
• • Note: Inflow treatment of non-target lesions is allowed provided successful treatment.
• • 5. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.
• • 6. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
• • 7. Subject has known allergy to urethane, nylon, or silicone.
• • 8. History of myocardial infarction within 60 days prior to enrollment.
• • 9. History of stroke within 60 days prior to enrollment.
• • 10. History of thrombolytic therapy within two weeks prior to enrollment.
• • 11. Subject has acute or chronic renal disease with creatinine \> 2.5 mg/dL, unless on dialysis.
• • 12. Subject is pregnant or nursing.
• • 13. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
• • 14. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
• • 15. The use of specialty balloons, re-entry or atherectomy devices.
• • 16. Active COVID-19 or previously diagnosed COVID-19 with sequelae that could confound endpoint assessments.
• • 17. Subject has an anticipated life span of less than one (1) year.
• • General Exclusion Criteria specific to BTK Arteries
• • 1. Subjects with osteomyelitis or deep soft tissue infection in the target limb.
• • 2. Acute limb ischemia (of either leg).
• • 3. Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot) in the target limb.
• • Angiographic Exclusion Criteria
• Subjects who meet any of the following exclusion criteria may not be enrolled in the study:
• • 1. In-stent restenosis within 10 mm of the target lesion.
• • 2. Lesion within 10 mm of the ostium of the SFA or within 10 mm proximal to the anterior tibial artery ostium. \<Not applicable to iliac or BTK cohort\>
• • 3. Evidence of aneurysm or thrombus in target vessel.
• • 4. No calcium or mild calcium in the target lesion by PACSS.
• • 5. Target lesion within native or synthetic vessel grafts.
• • 6. Subject has significant stenosis (≥ 50% stenosis) or occlusion of inflow tract before target treatment zone (e.g., iliac or common femoral) not successfully treated.
• • 7. Failure to successfully treat significant distal non-target lesions, if treated prior to target lesion. Successful treatment is defined as obtaining \< 50% residual stenosis with no serious angiographic complications (e.g., embolism).
• • 8. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.
• • Angiographic Exclusion Criteria specific to Iliac Arteries
• • 1.Target lesion with any aorta involvement.
• • Angiographic Exclusion Criteria specific to BTK Arteries
• • 1. Failure to treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries with \< 30% residual stenosis, and no serious angiographic complications (e.g., embolism).
• • 2. Treatment of vessels below the ankle joint.